The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started with a couple of interesting bolt-ons, and the typical incremental updates from across the industry. 

As always, our Evaluate Vantage team has brought together the highlights, along with context, views and what it really means for biopharma and investors alike. Check it out now. 



Day one sees buyers make the most of straitened times
Licensing deal flurry offers limited cash up front
Sutro makes its pitch to beat Immunogen
Novartis and Gilead’s interim halt hopes wane